Success Stories

Event Videos

COVID-19 in gastroenterology and hepatology: Lessons learned and questions to be answered https://pubmed.ncbi.nlm.nih.gov/34141782/ World J Clin Cases. 2021 Jun 16;9(17):4199-4209. doi: 10.12998/wjcc.v9.i17.4199. COVID-19 in gastroenterology and hepatology: Lessons learned and questions to be answered Shao Liu 1, Mi-Mi Tang 1, Jie Du 1, Zhi-Cheng Gong 1, Shu-Sen Sun 2 Abstract Background: Although coronavirus disease 2019 (COVID-19) presents primarily as a lower respiratory tract infection, increasing data suggests multiorgan, including the gastrointestinal (GI) tract and liver, involvement in patients who are infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Aim: To provide a comprehensive overview of COVID-19 in gastroenterology and hepatology. Published on: Jun-2021 Read more	Relationship Between Histological Features of Non-alcoholic Fatty Liver Disease and Ectopic Fat on Magnetic Resonance Imaging in Children and Adolescents https://pubmed.ncbi.nlm.nih.gov/34178902/ NAFLD Front Pediatr. 2021 Jun 10;9:685795. doi: 10.3389/fped.2021.685795. eCollection 2021. Relationship Between Histological Features of Non-alcoholic Fatty Liver Disease and Ectopic Fat on Magnetic Resonance Imaging in Children and Adolescents Eun Hye Lee 1, Ji Young Kim 2, Hye Ran Yang 3 4 Abstract Published on: Jun-2021 Read more
Metabolic Control and 'Ideal' Outcomes in Liver Transplantation for Maple Syrup Urine Disease https://pubmed.ncbi.nlm.nih.gov/34153280/ J Pediatr. 2021 Jun 18;S0022-3476(21)00558-8. doi: 10.1016/j.jpeds.2021.06.028.Online ahead of print. Metabolic Control and 'Ideal' Outcomes in Liver Transplantation for Maple Syrup Urine Disease Caroline B Ewing 1, Kyle A Soltys 2, Kevin A Strauss 3, Rakesh Sindhi 2, Jerry Vockley 4, Patrick McKiernan 5, Robert H Squires 5, Geoffrey Bond 2, Armando Ganoza 2, Ajai Khanna 2, George V Mazariegos 2, James E Squires 6 Objectives: To assess outcomes following liver transplantation for maple syrup urine disease (MSUD) by determining attainment and sustainability of metabolic control and apply an 'ideal' outcome composite in long-term survivors. Published on: Jun-2021 Read more	Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study https://pubmed.ncbi.nlm.nih.gov/34182185/ cholestatic liver disease Clin Res Hepatol Gastroenterol. 2021 Jun 25;101751. doi: 10.1016/j.clinre.2021.101751.Online ahead of print. Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study Ulrich Baumann 1, Ekkehard Sturm 2, Florence Lacaille 3, Emmanuel Gonzalès 4, Henrik Arnell 5, Björn Fischler 5, Marianne Hørby Jørgensen 6, Richard J Thompson 7, Jan P Mattsson 8, Mats Ekelund 8, Erik Lindström 8, Per-Göran Gillberg 8, Kristina Torfgård 8, Paresh N Soni 9 Abstract Published on: Jun-2021 Read more
Pediatric metabolic liver diseases: Evolving role of liver transplantation https://pubmed.ncbi.nlm.nih.gov/34164292/ Metabolic liver disease Review World J Transplant. 2021 Jun 18;11(6):161-179. doi: 10.5500/wjt.v11.i6.161. Pediatric metabolic liver diseases: Evolving role of liver transplantation Jagadeesh Menon 1, Mukul Vij 2, Deepti Sachan 3, Ashwin Rammohan 1, Naresh Shanmugam 1, Ilankumaran Kaliamoorthy 1, Mohamed Rela 1 Abstract Published on: Jun-2021 Read more	Acute liver injury among Pediatric Liver Transplantation recipients with COVID-19: An International Collaborative Study https://pubmed.ncbi.nlm.nih.gov/34183614/ transplant J Pediatr Gastroenterol Nutr. 2021 Jun 28. doi: 10.1097/MPG.0000000000003213.Online ahead of print. Acute liver injury among Pediatric Liver Transplantation recipients with COVID-19: An International Collaborative Study Priscila Sin 1, Luis Antonio Díaz, Mercedes Martínez, Cecilia Vizcaya, Daniel D'Agostino, Juan Cristóbal Gana Abstract Published on: Jun-2021 Read more
COVID-19 and pediatric fatty liver disease: Is there interplay? https://pubmed.ncbi.nlm.nih.gov/34168408/ NAFLD World J Gastroenterol. 2021 Jun 14;27(22):3064-3072. doi: 10.3748/wjg.v27.i22.3064. COVID-19 and pediatric fatty liver disease: Is there interplay? Anna Di Sessa 1, Francesca Lanzaro 2, Sarah Zarrilli 2, Vittorio Picone 2, Stefano Guarino 2, Emanuele Miraglia Del Giudice 2, Pierluigi Marzuillo 2 Abstract Published on: Jun-2021 Read more	Pediatric Wilson disease presenting as acute liver failure: Prognostic indices https://pubmed.ncbi.nlm.nih.gov/34002136/ Wilson disease World J Clin Cases. 2021 May 16;9(14):3273-3286. doi: 10.12998/wjcc.v9.i14.3273. Pediatric Wilson disease presenting as acute liver failure: Prognostic indices Wei-Yuan Fang 1, Kuerbanjiang Abuduxikuer 1, Peng Shi 2, Yi-Ling Qiu 1, Jing Zhao 1, Yu-Chuan Li 1, Xue-Yuan Zhang 1, Neng-Li Wang 1, Xin-Bao Xie 1, Yi Lu 3, A S Knisely 4, Jian-She Wang 1 Abstract Background: Acute liver failure (ALF) can be a primary presentation of Wilson disease (WD). Mortality rates are high in WD with ALF (WDALF). Predictions of mortality in WDALF vary by model and are sometimes contradictory, perhaps because few patients are studied or WD diagnoses are questionable. Published on: May-2021 Read more
Liver Involvement in Congenital Disorders of Glycosylation. A Systematic Review https://pubmed.ncbi.nlm.nih.gov/34173795/ J Pediatr Gastroenterol Nutr. 2021 Jun 24. doi: 10.1097/MPG.0000000000003209.Online ahead of print. Liver Involvement in Congenital Disorders of Glycosylation. A Systematic Review Rossella Colantuono 1, Elisa D'Acunto, Daniela Melis, Pietro Vajro, Hudson H Freeze, Claudia Mandato Abstract Published on: Jun-2021 Read more	Successful treatment of infantile hepatitis B with lamivudine: A case report https://pubmed.ncbi.nlm.nih.gov/34002156/ Hepatitis B Case Reports World J Clin Cases. 2021 May 16;9(14):3442-3448. doi: 10.12998/wjcc.v9.i14.3442. Successful treatment of infantile hepatitis B with lamivudine: A case report Yu-Ting Zhang 1, Jing Liu 1, Xiao-Ben Pan 1, Yi-Dan Gao 1, Yin-Fei Hu 2, Li Lin 3, Hua-Jun Cheng 4, Gong-Ying Chen 1 Abstract Background: How to treat infantile hepatitis B virus (HBV) infection remains a controversial issue. The nucleoside analogue lamivudine (LAM) has been approved to treat children (2 to 17 years old) with chronic hepatitis B. Here, we aimed to investigate the benefit of LAM treatment in infantile hepatitis B. Published on: May-2021 Read more

CLF Intro movie

SMS requests to

9224791366

Ask The Expert

Pediatric Liver Specialists in India

Centres offering Genetic Testing for Pediatric Liver Diseases

Financial Aid Offered by Trusts

Follow us on:

Facebook Twitter YouTube